A significant lower level of ALT level and a trend of lower AST were seen in notoginsenoside Fe-treated group compared to that in HF group, suggesting that notoginsenoside Fe improved liver function (Fig. 2C and D). The gene discussed is GPT; the disease is hydrops fetalis.